Cardinal Capital Management Has $8.24 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cardinal Capital Management increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.6% in the 3rd quarter, Holdings Channel reports. The fund owned 7,835 shares of the biopharmaceutical company’s stock after purchasing an additional 45 shares during the period. Regeneron Pharmaceuticals makes up about 1.3% of Cardinal Capital Management’s portfolio, making the stock its 25th biggest position. Cardinal Capital Management’s holdings in Regeneron Pharmaceuticals were worth $8,236,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of REGN. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $26,000. West Paces Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $998.23 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The company has a market cap of $110.04 billion, a P/E ratio of 26.44, a P/E/G ratio of 3.45 and a beta of 0.12. The business’s 50 day moving average is $1,112.39 and its two-hundred day moving average is $1,039.64. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $8.79 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on REGN shares. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 9th. Royal Bank of Canada lifted their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,116.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.